PharmGen Science, Inc.

KSE 004720.KS

PharmGen Science, Inc. Gross Profit Margin for the year ending December 31, 2023: 57.68%

PharmGen Science, Inc. Gross Profit Margin is 57.68% for the year ending December 31, 2023, a 7.08% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

PharmGen Science, Inc. Gross Profit Margin for the year ending December 31, 2022 was 53.87%, a -2.67% change year over year.
PharmGen Science, Inc. Gross Profit Margin for the year ending December 31, 2021 was 55.34%, a -0.24% change year over year.
PharmGen Science, Inc. Gross Profit Margin for the year ending December 31, 2020 was 55.48%, a 4.72% change year over year.
PharmGen Science, Inc. Gross Profit Margin for the year ending December 31, 2019 was 52.98%, a 2.17% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KSE: 004720.KS

PharmGen Science, Inc.

CEO	Lee Seung-Yeol
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	50, Jeyakgongdan 2-gil
Employees	248
Sector	Healthcare
Industries Pharmaceuticals Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It offers prescription drugs, OTC drugs, health food, and cosmetics. It offers its products in the form of tablet, hard capsule, granule and ointment, syrups, and suspension forms. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1961 and is headquartered in Hwaseong, South Korea.

Key trends

Past 5 years